Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $8000.0.

  • Seres Therapeutics' Capital Expenditures fell 9379.84% to $8000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $313000.0, marking a year-over-year decrease of 7317.91%. This contributed to the annual value of $380000.0 for FY2024, which is 9523.51% down from last year.
  • Per Seres Therapeutics' latest filing, its Capital Expenditures stood at $8000.0 for Q3 2025, which was down 9379.84% from $160000.0 recorded in Q2 2025.
  • Seres Therapeutics' Capital Expenditures' 5-year high stood at $4.1 million during Q3 2021, with a 5-year trough of $8000.0 in Q3 2025.
  • For the 5-year period, Seres Therapeutics' Capital Expenditures averaged around $1.5 million, with its median value being $1.2 million (2022).
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 610000.0% in 2021, then crashed by 9847.59% in 2024.
  • Seres Therapeutics' Capital Expenditures (Quarter) stood at $1.6 million in 2021, then soared by 119.33% to $3.5 million in 2022, then tumbled by 74.66% to $877000.0 in 2023, then crashed by 89.74% to $90000.0 in 2024, then crashed by 91.11% to $8000.0 in 2025.
  • Its Capital Expenditures stands at $8000.0 for Q3 2025, versus $160000.0 for Q2 2025 and $55000.0 for Q1 2025.